Literature DB >> 27041382

Predictors of remission, erosive disease and radiographic progression in a Colombian cohort of early onset rheumatoid arthritis: a 3-year follow-up study.

M A Quintana-Duque1, F Rondon-Herrera2, R D Mantilla2, E Calvo-Paramo3, J J Yunis4, A Varela-Nariño2, J F Restrepo2, A Iglesias-Gamarra2.   

Abstract

The objective of the study is to find predictors of remission, radiographic progression (RP), and erosive disease in a cohort of patients with early onset rheumatoid arthritis (EORA) that followed a therapeutic protocol aiming at remission, in a real world tight-control setting. EORA patients were enrolled in a 3-year follow-up study. Clinical, biological, immunogenetic, and radiographical data were analyzed. Radiographs were scored according to Sharp-van der Heijde (SvdH) method. RP was defined by an increase of 3 units in 36 months. Remission was defined as DAS28 <2.6. A stepwise multiple logistic regression model was used to identify independent predictors of the three target outcomes. One hundred twenty-nine patients were included. Baseline disease activity was high. Significant overall improvement was observed, but only 33.3 % achieved remission. At 36 month, 50.4 % (65) of patients showed erosions. RP was observed in 62.7 % (81) of cases. Statistical analysis showed that baseline SvdH score was the only predictive factor associated with the three outcomes evaluated. Lower HAQ-DI and absence of autoantibodies were predictive of remission. Higher levels of ESR and presence of erosions at entry were predictive of RP. Independent baseline predictors of incident erosive disease were anti-CCP and RF positivity, symptom duration at baseline >3 months, and presence of HLA-DRB1 shared epitope. Radiographic damage at baseline was the main predictor of outcomes. Autoantibodies, HAQ and ESR at baseline, symptom duration before diagnosis, and HLA-DRB1 status had influence on clinical course and development of structural joint damage in Colombian RA patients.

Entities:  

Keywords:  Disease activity; Early onset rheumatoid arthritis; Erosions; Radiographic progression

Mesh:

Substances:

Year:  2016        PMID: 27041382     DOI: 10.1007/s10067-016-3246-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  45 in total

1.  Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a followup study.

Authors:  D van Zeben; J M Hazes; A H Zwinderman; A Cats; G M Schreuder; J D'Amaro; F C Breedveld
Journal:  Arthritis Rheum       Date:  1991-07

2.  A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study.

Authors:  P Brennan; B Harrison; E Barrett; K Chakravarty; D Scott; A Silman; D Symmons
Journal:  BMJ       Date:  1996-08-24

3.  The -308 G/A polymorphism in the tumor necrosis factor-α gene is not associated with development and progression of rheumatoid arthritis in Argentinean patients.

Authors:  Federico Aranda; Silvia D Perés Wingeyer; Emilce Schneeberger; María Valerio; Emilia Saint Martin; Fernando Dal Pra; María de Los Ángeles Correa; Gustavo Citera; Liliana Martínez; Pablo Mannucci; Graciela Remondino; Gabriela F de Larrañaga
Journal:  Int J Rheum Dis       Date:  2014-03-27       Impact factor: 2.454

4.  Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference.

Authors:  Karin Bruynesteyn; Désirée van der Heijde; Maarten Boers; Ariane Saudan; Paul Peloso; Harold Paulus; Harry Houben; Bridget Griffiths; John Edmonds; Barry Bresnihan; Annelies Boonen; Sjef van der Linden
Journal:  Arthritis Rheum       Date:  2002-04

5.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Authors:  Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green
Journal:  Arthritis Rheum       Date:  2006-01

6.  The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis.

Authors:  E J Kroot; B A de Jong; M A van Leeuwen; H Swinkels; F H van den Hoogen; M van't Hof; L B van de Putte; M H van Rijswijk; W J van Venrooij; P L van Riel
Journal:  Arthritis Rheum       Date:  2000-08

7.  Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS.

Authors:  Keeranur Jayakumar; Sam Norton; Josh Dixey; David James; Andrew Gough; Peter Williams; Peter Prouse; Adam Young
Journal:  Rheumatology (Oxford)       Date:  2011-11-16       Impact factor: 7.580

8.  Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study.

Authors:  L Gossec; M Dougados; P Goupille; A Cantagrel; J Sibilia; O Meyer; J Sany; J-P Daurès; B Combe
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

9.  Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study.

Authors:  E W Karlson; L B Chibnik; J Cui; R M Plenge; R J Glass; N E Maher; A Parker; R Roubenoff; E Izmailova; J S Coblyn; M E Weinblatt; N A Shadick
Journal:  Ann Rheum Dis       Date:  2007-07-31       Impact factor: 19.103

10.  Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study.

Authors:  Elisa Gremese; Fausto Salaffi; Silvia Laura Bosello; Alessandro Ciapetti; Francesca Bobbio-Pallavicini; Roberto Caporali; Gianfranco Ferraccioli
Journal:  Ann Rheum Dis       Date:  2012-07-13       Impact factor: 19.103

View more
  5 in total

1.  Serum level of reactive oxygen metabolites (ROM) at 12 weeks of treatment with biologic agents for rheumatoid arthritis is a novel predictor for 52-week remission.

Authors:  Arata Nakajima; Yasuchika Aoki; Masato Sonobe; Hiroshi Takahashi; Masahiko Saito; Koichi Nakagawa
Journal:  Clin Rheumatol       Date:  2016-11-17       Impact factor: 2.980

2.  Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort.

Authors:  Rocio V Gamboa-Cárdenas; Manuel F Ugarte-Gil; Massardo Loreto; Mónica P Sacnun; Verónica Saurit; Mario H Cardiel; Enrique R Soriano; Cecilia Pisoni; Claudio M Galarza-Maldonado; Carlos Rios; Sebastião C Radominski; Geraldo da R Castelar-Pinheiro; Washington Alves Bianchi; Simone Appenzeller; Inés Guimarães da Silveira; Cristiano A de Freitas Zerbini; Carlo V Caballero-Uribe; Adriana Rojas-Villarraga; Marlene Guibert-Toledano; Francisco Ballesteros; Rubén Montufar; Janitzia Vázquez-Mellado; Jorge Esquivel-Valerio; Ignacio García De La Torre; Leonor A Barile-Fabris; Fedra Irazoque Palezuelos; Lilia Andrade-Ortega; Pablo Monge; Raquel Teijeiro; Ángel F Achurra-Castillo; María H Esteva Spinetti; Graciela S Alarcón; Bernardo A Pons-Estel
Journal:  Clin Rheumatol       Date:  2019-06-03       Impact factor: 2.980

3.  Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 Genes Are Associated with the Response to TNF Inhibitors in Patients with Rheumatoid Arthritis.

Authors:  Paola Conigliaro; Cinzia Ciccacci; Cristina Politi; Paola Triggianese; Sara Rufini; Barbara Kroegler; Carlo Perricone; Andrea Latini; Giuseppe Novelli; Paola Borgiani; Roberto Perricone
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

4.  Increased remission with fewer corticosteroids and more biologics in rheumatoid arthritis at 7-year follow-up in real-life conditions.

Authors:  Guillaume Larid; Justine Vix; Ronan Garlantezec; Elodie Loppin; Elisabeth Gervais
Journal:  Sci Rep       Date:  2022-02-15       Impact factor: 4.379

5.  Serum Reactive Oxygen Metabolites as a Predictor of Clinical Disease Activity Index, Simplified Disease Activity Index, and Boolean Remissions in Rheumatoid Arthritis Patients Treated With Biologic Agents.

Authors:  Arata Nakajima; Keiichiro Terayama; Masato Sonobe; Yorikazu Akatsu; Junya Saito; Masaki Norimoto; Shinji Taniguchi; Ayako Kubota; Yasuchika Aoki; Koichi Nakagawa
Journal:  Cureus       Date:  2021-11-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.